The Shareholder of ImmunoPrecise Antibodies (Other OTC: IPATF) is Selling Shares

By Carrie Williams

Today, the Shareholder of ImmunoPrecise Antibodies (IPATFResearch Report), Miko Malberg, sold shares of IPATF for $1.62M.

In addition to Miko Malberg, one other IPATF executive reported Sell trades in the last month.

See today’s analyst top recommended stocks >>

Based on ImmunoPrecise Antibodies’ latest earnings report for the quarter ending April 30, the company posted quarterly revenue of $4.15 million and GAAP net loss of -$945,846. In comparison, last year the company earned revenue of $2.64 million and had a GAAP net loss of $3.84 million. Currently, ImmunoPrecise Antibodies has an average volume of 135.24K. The company has a one-year high of $1.88 and a one-year low of $0.23.

The insider sentiment on ImmunoPrecise Antibodies has been negative according to 37 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ImmunoPrecise Antibodies Ltd. engages in the provision of integrated antibody solutions. It services include human monoclonals, hybridoma development, rabbit monoclonals, b-cell select, phage display, cryostorage, hybridoma sequencing, antibody generation, anti-body purification, polyclonal production, and peptide production. The company was founded by Robert Beecroft in 1989 and is headquartered in Victoria, Canada.